Steroid Dependent/Refractory Chronic GVHD

Criteria to qualify for study: Drug used in study:
  • Persistent cGVHD manifestations requiring a glucocorticoid dose ≥ prednisone 0.25 mg/kg/day
  • Refractory disease - Progressive cGVHD manifestations despite treatment with a glucocorticoid dose >= prednison 0.5 mg/kg/day

Stanford University CBCI-217

A Phase 1 Study of Nilotnib in Steroid Dependent / Refractory Chronic Graft Versus Host Disease.

X Study Closed